Shares of Haemonetics Corporation (NYSE:HAE) have been assigned a consensus rating of “Hold” from the ten analysts that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $39.83.

HAE has been the topic of several recent analyst reports. TheStreet raised Haemonetics Corporation from a “c” rating to a “b-” rating in a research report on Monday, August 7th. Zacks Investment Research raised Haemonetics Corporation from a “hold” rating to a “buy” rating and set a $47.00 target price on the stock in a research report on Wednesday, August 9th. Jefferies Group LLC reaffirmed a “buy” rating and set a $48.00 target price on shares of Haemonetics Corporation in a research report on Thursday, July 27th. Finally, JMP Securities raised Haemonetics Corporation from a “market perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Thursday, July 13th.

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Verition Fund Management LLC purchased a new position in shares of Haemonetics Corporation during the second quarter worth $452,000. Piedmont Investment Advisors LLC purchased a new position in shares of Haemonetics Corporation during the second quarter worth $448,000. Susquehanna International Group LLP purchased a new position in shares of Haemonetics Corporation during the second quarter worth $445,000. The Manufacturers Life Insurance Company raised its position in shares of Haemonetics Corporation by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 39,906 shares of the medical instruments supplier’s stock worth $1,575,000 after buying an additional 488 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in shares of Haemonetics Corporation during the second quarter worth $6,115,000.

WARNING: This news story was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.watchlistnews.com/haemonetics-corporation-hae-receives-average-rating-of-hold-from-analysts/1530444.html.

Shares of Haemonetics Corporation (NYSE HAE) traded down 0.79% during mid-day trading on Tuesday, reaching $41.45. 161,930 shares of the company’s stock were exchanged. The stock has a 50-day moving average of $40.94 and a 200 day moving average of $40.32. Haemonetics Corporation has a one year low of $32.76 and a one year high of $43.74. The firm has a market capitalization of $2.18 billion, a P/E ratio of 538.31 and a beta of 0.90.

Haemonetics Corporation (NYSE:HAE) last announced its earnings results on Monday, August 7th. The medical instruments supplier reported $0.33 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.02. Haemonetics Corporation had a return on equity of 11.07% and a net margin of 0.48%. The company had revenue of $211 million for the quarter, compared to analyst estimates of $211.29 million. During the same period in the prior year, the company posted $0.25 EPS. The firm’s quarterly revenue was up .5% compared to the same quarter last year. On average, analysts forecast that Haemonetics Corporation will post $1.60 EPS for the current fiscal year.

Haemonetics Corporation Company Profile

Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company’s segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals.

Analyst Recommendations for Haemonetics Corporation (NYSE:HAE)

Receive News & Ratings for Haemonetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.